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The reservoir and mode of transmission of Pneumo-
cystis jirovecii remain uncertain. We conducted a cross-
sectional study of 126 San Francisco General Hospital staff 
in clinical (n = 103) and nonclinical (n = 23) occupations to 
assess whether occupational exposure was associated with 
immune responses to P. jirovecii. We examined antibody 
levels by ELISA for 3 overlapping fragments that span the 
P. jirovecii major surface glycoprotein (Msg): MsgA, MsgB, 
and MsgC1. Clinical occupation participants had higher 
geometric mean antibody levels to MsgC1 than did nonclini-
cal occupation participants (21.1 vs. 8.2, p = 0.004); clinical 
occupation was an independent predictor of higher MsgC1 
antibody levels (parameter estimate = 0.89, 95% confidence 
interval 0.29–1.48, p = 0.003). In contrast, occupation was 
not significantly associated with antibody responses to ei-
ther MsgA or MsgB. Healthcare workers may have occupa-
tional exposure to P. jirovecii. Humans may be a reservoir 
for P. jirovecii and may transmit it from person to person.
Although the incidence of Pneumocystis jirovecii pneu-monia (PCP) has declined in the era of combination 
antiretroviral therapy, PCP remains the most common se-
rious opportunistic infection among human immunodefi-
ciency virus (HIV)-infected persons in the United States 
(1). The reservoir and mode of transmission of P. jirovecii 
remain uncertain because of an inability to grow the organ-
ism in vitro. However, studies of immune responses to P. 
jirovecii have provided important insights into its epide-
miology, showing that up to 80%–100% of children have 
detectable P. jirovecii antibodies by 8 years of age (2–9). 
These findings suggest that P. jirovecii is ubiquitous, that 
humans are exposed to P. jirovecii early in life, and that 
PCP that develops later in life results from reactivation of 
latent infection.
Emerging evidence suggests that PCP also can result 
from recent acquisition of P. jirovecii, and the organism may 
be transmitted from person to person (10,11). In the hospi-
tal or clinic, numerous PCP outbreaks have been reported 
among immunocompromised patients who shared common 
healthcare workers (HCWs), hospital rooms, wards, or clin-
ics (12–21). In the laboratory, animal-to-animal transmis-
sion of Pneumocystis spp. has been demonstrated both by 
immunocompromised and immunocompetent hosts after 
periods of exposure as short as 1 day (22,23). Dumoulin et 
al. demonstrated that immunocompetent mice became tran-
siently colonized with Pneumocystis spp. after contact with 
Pneumocystis-infected mice and then were able to trans-
mit the infection to Pneumocystis-free mice that had severe 
combined immunodeficiency (23).
Several studies have found that P. jirovecii can colo-
nize immunocompetent humans and suggest that such per-
sons may serve as potential reservoirs (24). The question 
that arises is whether person-to-person transmission occurs 
through immunocompetent hosts, such as HCWs, who may 
be transiently colonized with P. jirovecii during brief clini-
cal interactions with PCP patients and subsequently trans-
mit the infection to other immunocompromised patients. 
Prior studies involving HCWs used different specimens 
(e.g., induced sputum, oropharyngeal wash, nasal rinse, 
deep nasal swab, blood) and different laboratory methods 
(i.e., different PCRs and ELISAs) to compare exposed and 
unexposed groups, making findings difficult to compare 
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across studies (25–31). In addition, these studies compared 
different groups of HCWs and did not include a control 
group without patient contact.
Therefore, we performed a cross-sectional study of 
hospital staff at San Francisco General Hospital (SFGH) 
in both clinical (exposed) and nonclinical (unexposed) oc-
cupations. Our goal was to determine whether HCW occu-
pation was associated with antibody levels to P. jirovecii. 
Finding this association would suggest that HCWs may 
acquire P. jirovecii and potentially be a reservoir in the 
hospital setting.
Methods
Participants
We recruited participants from the Department of 
Medicine, the Division of Pulmonary and Critical Care 
Medicine, and the HIV/AIDS Division because members 
of these groups provide the most care to patients with HIV 
infection or PCP, our hypothesized primary reservoirs of 
P. jirovecii. We recruited by word of mouth; emails to de-
partmental listservs; and announcements at medical confer-
ences, staff meetings, and orientations for medical students 
and residents. From January 2007 through February 2008, 
we enrolled 126 SFGH staff. We included staff who worked 
at the hospital during the study period, provided informed 
consent, and had no clinical evidence of PCP. The Uni-
versity of California, San Francisco, and the University of 
Cincinnati institutional review boards approved the study.
Questionnaire
We collected information by using a standardized 
participant-completed questionnaire. In addition to de-
mographic characteristics, we obtained information about 
occupation, department/division, percentage of time spent 
seeing patients, and past exposure to patients with PCP. 
These questions were designed to assess patient contact 
in general and contact with PCP patients specifically. We 
also obtained information about cigarette smoking, chronic 
lung disease (e.g., chronic obstructive pulmonary disease), 
and immunocompromising conditions (e.g., HIV infection 
or use of immunosuppressive medications) because these 
factors have been associated with P. jirovecii colonization 
(24). To protect our colleagues’ confidentiality regarding 
their medical history, we asked participants to check yes 
if they had >1 condition from a list of pulmonary or im-
munocompromising conditions, without requiring them to 
specify the condition. For example, participants were asked 
to reply yes or no to the following question: “Do you have 
any of the following conditions? HIV, cancer including 
leukemia/lymphoma, organ transplant, bone marrow trans-
plant, steroid medication (e.g., prednisone), chemotherapy 
medication, immunosuppressive medication (e.g., metho-
trexate, rituximab, cyclosporine, tacrolimus, azathioprine, 
cyclophosphamide), pregnancy,” but participants were not 
required to disclose the specific immune disorder (e.g., 
HIV infection, cancer).
Classification of Participants
We classified staff into 2 groups: those with patient 
contact (clinical occupation group, n = 103) and those with-
out contact with patients or clinical samples from patients 
(nonclinical occupation group, n = 23). The clinical group 
was further subdivided into staff who provide direct pa-
tient care (e.g., physicians and nurses) and staff who pro-
vide indirect patient care or ancillary services (e.g., medical 
assistants, social workers, and pharmacists). Because each 
department/division has defined space on the SFGH cam-
pus, people from the same department/division generally 
have offices in the same location. However, those in the 
clinical occupation group also work in the hospital wards, 
clinics, or clinical research units and have contact with pa-
tients, whereas those in the nonclinical group have no oc-
cupational contact with patients.
Serum ELISA
We collected a serum specimen from each participant 
and stored it at −80ºC before shipping it to the University of 
Cincinnati. We used a previously described ELISA (32,33) 
to measure immunoglobulin G levels to 3 overlapping frag-
ments that span the length of the P. jirovecii major surface 
glycoprotein (Msg): MsgA, MsgB, and MsgC1 (Figure 1). 
MsgA is the amino terminus, MsgB is the middle portion, 
and MsgC is the carboxyl terminus (34). MsgC1 is 1 of 4 
MsgC variants we have generated and can be used to distin-
guish between HIV-infected patients with and without PCP 
on the basis of antigenic recognition (33). We tested par-
ticipant serum specimens and the reference serum against 
Msg fragments and used phosphate-buffered saline as a 
negative control. We corrected the reactivity of each serum 
specimen to Msg by subtracting the reactivity of that serum 
to phosphate-buffered saline and quantified the results by 
using the method of Bishop and Kovacs (35). A standard 
curve generated for each Msg construct was used to cal-
culate the units of reactivity. We assigned to each standard 
serum pool a value of 100 U of reactivity to its target Msg 
construct in 100 µL of a 1:100 dilution. We assayed test 
specimens at 1:100–1:200 dilutions to fit the linear portion 
of the standard curves and calculated units of reactivity. 
Samples with values below the standard curve were as-
signed the lowest possible value of 1 U.
Statistical Analysis
The laboratory group was blinded to the clinical data, 
and the clinical group was blinded to the laboratory results. 
Prespecified primary predictors of interest were profession-
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 10, October 2009 1591 
RESEARCH
al and health characteristics. The outcome of interest was 
Msg antibody level, a continuous variable, which we log 
transformed to better approximate a normal distribution. 
We calculated the mean log Msg level for each predictor 
variable and examined bivariate associations using Student 
t test. The data were then converted to the original scale 
and presented as geometric means (GMs). For associations 
with p<0.1 in bivariate analysis, we performed multivariate 
linear regression using the natural log of Msg level as the 
dependent variable and considered a 2-tailed p<0.05 to be 
statistically significant. All statistics were calculated using 
SAS software, version 9.1 (SAS Institute Inc., Cary, NC, 
USA).
Results
Participants
We enrolled 126 staff. Mean age of participants was 
39.6 years (range 22–80 years), 57.1% were female, 60.2% 
were white/Caucasian, 25.2% were Asian, 16.0% were 
Hispanic/Latino, and 3.3% were black/African American 
(Table 1). Forty-two (33.6%) had smoked at least 100 ciga-
rettes in their lifetime, and 16.0% had chronic lung disease, 
including asthma (n = 17) and interstitial lung disease (n = 
1). Overall, 6.4% had an immunocompromising condition. 
Participants were primarily from the HIV/AIDS Division 
(44.4%), the Division of Pulmonary and Critical Care Med-
icine (26.2%), and the Department of Medicine (23.0%). A 
few participants (6.4%) were from other departments (Ob-
stetrics and Gynecology, Psychiatry, and Radiology) and 
were involved in the care of HIV-infected or PCP patients. 
Eighty-five (67.5%) participants reported prior exposure to 
a PCP patient.
Clinical and Nonclinical Occupation Groups
We classified 103 (81.7%) participants into the clinical 
occupation group and 23 (18.3%) into the nonclinical occu-
pation group. The clinical group consisted of 27 attending 
physicians; 17 residents and fellows; 19 medical students; 
9 nurse practitioners; 10 nurses; 10 ancillary clinic staff, 
including medical assistants, social workers, pharmacists, 
and clinic managers; and 11 clinical research personnel. 
The nonclinical group consisted of 18 administrative staff 
and 5 laboratory personnel. These 2 groups did not differ 
significantly in terms of demographic characteristics (Ta-
ble 1). However, a significantly greater proportion of the 
nonclinical group than the clinical group reported having 
an immunocompromising condition (17.4% vs. 3.9%, p = 
0.04), and a significantly greater proportion of the clinical 
group than the nonclinical group reported prior exposure 
to a PCP patient (83 [80.6%] of 103 vs. 2 [8.7%] of 23, 
p<0.001).
Antibody Levels to MsgA, MsgB, and MsgC1
Participants had detectable antibody levels to MsgA 
(GM 11.8, 95% CI 8.1–17.0), MsgB (GM 2.6, 95% confi-
dence interval [CI] 2.1–3.1), and MsgC1 (GM 17.8, 95% 
CI 13.8–22.9) (Table 2). Antibody responses were detect-
ed in participants from all demographic groups, in smok-
ers and nonsmokers, and in participants with and without 
chronic lung disease or immunocompromising condition. 
Responses also were detected in participants with and with-
out exposure to a PCP patient and in both the clinical and 
nonclinical groups.
Antibody levels to MsgA or MsgB did not differ sig-
nificantly by age, sex, race, ethnicity, smoking status, pres-
ence of chronic lung disease, or presence of immunocom-
promising condition (Table 2). Similarly, MsgA or MsgB 
levels did not differ significantly between participants with 
and without exposure to a PCP patient or between the clini-
cal and nonclinical groups.
In contrast, antibody levels to MsgC1 differed signifi-
cantly (Table 2). Participants >60 years of age had signifi-
cantly lower GM antibody levels than all others (4.8 vs. 
19.1, p = 0.03); Asians had higher GM antibody levels than 
non-Asians (27.5 vs. 15.3, p = 0.05); and men had non-
significantly higher GM antibody levels than women (22.7 
vs. 14.8, p = 0.1). In contrast to the findings for MsgA and 
MsgB, participants in the clinical occupation group had sig-
nificantly higher GM MsgC1 antibody levels than those in 
the nonclinical occupation group (21.1 vs. 8.2, p = 0.004).
Predictors of MsgC1 Antibody Levels
To identify independent predictors of antibody levels 
to MsgC1, we performed multivariate linear regression and 
included in the model variables that had p<0.1 in bivariate 
analysis: older age, Asian race, sex, and clinical occupa-
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 Figure 1. Pneumocystis jirovecii major surface glycoprotein (Msg) 
fragments. Lengths of Msg fragments are expressed on a nucleotide 
scale. MsgA is the amino terminus, MsgB is the middle portion, and 
MsgC1 is the carboxyl terminus of the protein.
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tion. Clinical occupation (p = 0.003) and age >60 years (p 
= 0.03) were the only significant independent predictors of 
MsgC1 antibody response when we controlled for other 
factors (Table 3). Because the proportion of persons with 
immunocompromising conditions differed between the 
clinical and nonclinical groups, we included this variable 
in a subsequent model and found that it strengthened the 
association between clinical occupation and MsgC1 levels 
(coefficient 0.98, 95% CI 0.38–1.58, p = 0.001).
The GM MsgC1 antibody level was significantly high-
er in the clinical than in the nonclinical occupation group. 
Within the clinical group, we examined the association be-
tween direct patient care occupations and indirect patient 
care occupations and MsgC1 antibody levels. We found no 
significant difference in GM MsgC1 antibody levels be-
tween these 2 groups (21.8 for direct care group vs. 18.8 for 
indirect care group, p = 0.64). Finally, when we examined 
the association between individual occupations and MsgC1 
antibody levels (Figure 2), medical students (28.8) and res-
idents/fellows (32.5) had the highest GM MsgC1 antibody 
levels of all participants. Laboratory staff had the lowest 
GM levels (4.2), but these levels did not differ significantly 
from those of administrative staff (9.9) (p = 0.33).
Discussion
We investigated whether HCW occupation was asso-
ciated with immune response to P. jirovecii. Staff in the 
clinical occupation group had significantly higher antibody 
levels to MsgC1 than did those in the nonclinical occupa-
tion group, and clinical occupation was the most signifi-
cant predictor of MsgC1 antibody levels. In contrast, HCW 
occupation was not significantly associated with antibody 
levels to either MsgA or MsgB.
Why did we find an association between occupation 
and MsgC1 but not MsgA or MsgB antibody levels? Ms-
gC1 is the most conserved of the 3 Msg fragments studied 
(36). When a person is repeatedly exposed to P. jirovecii, 
MsgC1 possibly acts as a recall antigen and elicits higher 
amnestic responses than primary antigens, such as MsgA 
and MsgB. Previously, we found a significant association 
between HIV-infected patients with PCP and changes in 
MsgC1 antibody levels but not with MsgA or MsgB an-
tibody levels (37). In PCP patients, antibody levels of 
MsgC1, but not MsgA or MsgB, increased significantly 
from baseline to weeks 3–4 (after treatment completion). 
Furthermore, MsgC1 antibody levels increased only in 
patients with PCP; levels remained unchanged in pa-
tients with non-P. jirovecii pneumonia. Thus, increases in 
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Table 1. Characteristics of participants in a study of Pneumocystis jirovecii antibody levels* 
Characteristic Total, no. (%), N = 126 Clinical, no. (%), n = 103 Nonclinical, no. (%), n = 23 p value 
Demographics 
 Age group, y 
? ? <30 33 (26.6) 30 (29.7) 3 (13.0) Ref
  31–40 38 (30.7) 31 (30.7) 7 (30.4) 0.98
  41–50 27 (21.8) 20 (19.8) 7 (30.4) 0.35
  51–60 21 (16.9) 16 (15.8) 5 (21.7) 0.53
  >60 5 (4.0) 4 (4.0) 1 (4.4) 0.92
 Sex 
  F 72 (57.1) 57 (55.3) 15 (65.2) 0.39
  M 54 (42.9) 46 (44.7) 8 (34.8) Ref
 Race 
  White/Caucasian 74 (60.2) 60 (60.0) 14 (60.9) Ref
  Asian 31 (25.2) 27 (27.0) 4 (17.4) 0.14
  Black/African American 4 (3.3) 2 (2.0) 2 (8.7) 0.14
  Other 14 (11.4) 11 (11.0) 3 (13.0) 0.82
  Hispanic/Latino ethnicity 20 (16.0) 14 (13.7) 6 (26.1) 0.20
Health conditions 
 Ever smoked 42 (33.6) 32 (31.4) 10 (43.5) 0.27
 Lung condition 20 (16.0) 14 (13.7) 6 (26.1) 0.20
 Immune condition 8 (6.4) 4 (3.9) 4 (17.4) 0.04
Professional characteristics 
 Department/division 
  HIV/AIDS 56 (44.4) 45 (43.7) 11 (47.8) Ref
  Pulmonary and CCM 33 (26.2) 28 (27.2) 5 (21.7) 0.42
  Medicine 29 (23.0) 25 (24.3) 4 (17.4) 0.32
  Other 8 (6.4) 5 (4.9) 3 (13.0) 0.14
 Ever exposed to PCP patient 85 (67.5) 83 (80.6) 2 (8.7) <0.001
*Ref, reference category; CCM, critical care medicine; PCP, P. jirovecii pneumonia. Participants in this cross-sectional study were healthcare staff 
recruited during January 2007–February 2008 from San Francisco General Hospital. Mean ages (y ± SD) of participants: total, 39.6 ± 11.7; clinical, 39.1 ± 
11.9; nonclinical, 42.0 ± 10.4 (p = 0.29).  
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MsgC1 levels may indicate recovery from or recent expo-
sure to PCP, and this assay may be a useful epidemiologic 
tool for studying P. jirovecii infection.
The MsgC1 assay may also be useful in the study of 
P. jirovecii exposure and colonization. In the laboratory, 
Pneumocystis colonizes immunocompetent animals after 
they are exposed to either animals with Pneumocystis pneu-
monia or animals colonized with Pneumocystis (22,23). 
Colonized animals remain without evidence of pneumonia 
but can serve as a source of Pneumocystis because Pneu-
mocystis pneumonia develops in immunocompromised 
animals subsequently placed in contact with them. These 
findings suggest that HCWs exposed to patients with PCP 
(or persons colonized with P. jirovecii) can become colo-
nized with P. jirovecii and that the MsgC1 ELISA might 
be used as an indication of this colonization, although the 
precise relation between antibody levels and P. jirovecii 
colonization has yet to be fully determined.
Prior studies of P. jirovecii exposure and coloniza-
tion in HCWs have yielded mixed results. Girón et al. ob-
served that antibody levels in intensive care unit staff rose 
after exposure to a PCP patient, whereas those of control 
staff did not (25). Leigh et al. found that antibody levels 
of HCWs caring for patients with AIDS were significantly 
higher than those in control workers caring for elderly pa-
tients (26). Vargas et al. detected P. jirovecii DNA in deep 
nasal swab samples of 2 HCW contacts and 1 family con-
tact of a PCP patient, compared with no detectable DNA in 
control HCWs who did not enter the patient’s room (29). 
Likewise, Miller et al. demonstrated that HCWs in an HIV/
AIDS unit were more likely to have detectable P. jirovecii 
DNA in induced sputum and nasal rinse samples than were 
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Table 2. Bivariate associations with Pneumocystis jirovecii Msg levels*  
MsgA MsgB MsgC1
Characteristic
No.
persons GM (95% CI) p value GM (95% CI) p value GM (95% CI) p value 
Total 126 11.8 (8.1–17.0) 2.6 (2.1–3.1) 17.8 (13.8–22.9) 
Demographics 
 Age group, y 
? ? <30 33 12.0 (5.4–26.8) Ref 2.5 (1.7–3.7) Ref 16.3 (9.5–28.0) Ref
  31–40 38 11.0 (5.7–21.3) 0.86 2.7 (1.8–3.9) 0.84 22.6 (14.9–34.4) 0.33
  41–50 27 10.1 (4.5–22.4) 0.75 2.4 (1.6–3.7) 0.88 19.8 (11.6–33.7) 0.61
  51–60 21 17.2 (6.3–46.4) 0.57 2.4 (1.4–4.2) 0.90 17.4 (8.8–34.3) 0.88
  >60 5 12.8 (0.7–243.0) 0.95 3.3 (0.3–32.8) 0.66 4.8 (0.7–34.7) 0.11
 Sex 
  M 54 14.3 (8.2–25.2) 0.37 2.9 (2.1–4.0) 0.26 22.7 (16.0–32.1) 0.10
  F 72 10.2 (6.2–16.7) 2.3 (1.8–3.0) 14.8 (10.4–21.2) 
 Race 
  Asian 31 6.6 (3.1–14.4) 0.08 2.3 (1.6–3.3) 0.49 27.5 (17.6–42.9) 0.05
  Other 92 14.4 (9.4–22.1) 2.7 (2.1–3.5) 15.3 (11.2–20.7) 
 Ethnicity 
 Hispanic/Latino 20 12.5 (5.5–28.5) 0.92 1.9 (1.3–2.7) 0.17 13.4 (6.2–29.1) 0.35
 Non–Hispanic/Latino 105 11.9 (7.9–18.1) 2.7 (2.2–3.5) 18.7 (14.2–24.4) 
Health conditions 
 Smoked 
  Ever 42 13.9 (7.1–27.1) 0.58 2.8 (1.9–4.1) 0.63 13.2 (8.4–20.9) 0.11
  Never 83 11.2 (7.1–17.5) 2.5 (2.0–3.2) 20.5 (15.1–27.8) 
 Lung condition 
  Yes 20 11.3 (4.4–28.7) 0.88 2.5 (1.5–4.1) 0.83 14.1 (7.2–27.5) 0.45
  No 105 12.2 (8.1–18.3) 2.6 (2.1–3.3) 18.5 (14.0–24.4) 
 Immune condition 
  Yes 8 13.1 (2.6–66.6) 0.90 2.9 (0.8–10.0) 0.76 24.0 (13.6–42.3) 0.26
  No 117 11.9 (8.1–17.6) 2.6 (2.1–3.1) 17.3 (13.2–22.7) 
Professional characteristics 
 Exposed to PCP patient 
  Ever 85 13.1 (8.3–20.7) 0.41 2.6 (2.0–3.3) 0.99 20.8 (15.8–27.3) 0.11
  Never 41 9.4 (4.9–18.0) 2.6 (1.8–3.6) 12.9 (7.5–21.9) 
 Occupation 
  Clinical 103 13.4 (8.9–20.1) 0.14 2.6 (2.1–3.3) 0.80 21.1 (16.3–27.3) 0.004
  Nonclinical 23 6.6 (2.6–16.6) 2.4 (1.5–4.0) 8.2 (4.0–17.0) 
*Msg, major surface glycoprotein; GM, geometric mean; CI, confidence interval; Ref, reference category; PCP, P. jirovecii pneumonia. Serum antibody 
levels were calculated from standard curves derived by using a standard serum pool with an assigned value of 100 U; specimens below the curve were 
assigned the lowest possible value (1 U). Predictor variables were compared with the natural log of Msg levels using Student t test, then converted back 
to the original scale and presented as GM. Participants in this cross-sectional study were healthcare staff recruited during January 2007–February 2008 
from San Francisco General Hospital. 
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those working on a general medical–respiratory unit (30). 
Durand-Joly et al. longitudinally followed HCWs with 
oropharyngeal washes and found P. jirovecii DNA in 10 
(6.1%) of 164; duration of carriage ranged from 3 to 10 
weeks (31).
In contrast, other studies found no evidence of P. 
jirovecii colonization in HCWs. Lundgren et al. found no 
difference in the frequency or level of P. jirovecii Msg an-
tibodies between HCWs caring for PCP patients in an in-
fectious diseases department and control staff from a blood 
bank and surgical department (28). In addition, they were 
unable to detect P. jirovecii DNA in oropharyngeal washes. 
Similarly, Lidman and colleagues found no evidence of P. 
jirovecii DNA in sputum samples from nurses caring for 
a PCP patient, and only 2 (8%) of 26 had detectable an-
tibodies to P. jirovecii (27). The conflicting results from 
these studies may be due to several factors, including dif-
ferences in types of staff recruited, specimens collected, 
or assays used. Staff working in different clinical depart-
ments are likely to have differing degrees of exposure to 
PCP patients. For example, HCWs working on an HIV/
AIDS unit (Miller et al. study) may have cared for more 
PCP patients than did those working in a general infectious 
diseases department (Lundgren et al. study). This differ-
ence in P. jirovecii exposure may have contributed to posi-
tive findings in the first study and negative findings in the 
second. In addition, different respiratory specimens have 
different degrees of invasiveness and different organismal 
yields, ranging from more invasive bronchoalveolar lavage 
to less invasive oropharyngeal washes. Similarly, different 
assays have varying sensitivities for detecting the organ-
ism. Among the DNA-based assays, nested PCR is more 
sensitive than single-round PCR for detecting P. jirovecii 
DNA. For serum assays, ELISA may be more sensitive but 
Western blot is more specific. Prevalence of the organism 
also may differ in different geographic regions, as has been 
seen in various European populations (4,38,39).
Our observation of higher MsgC1 antibody levels in 
clinical staff than in nonclinical staff is consistent with 
the possibility of nosocomial transmission of P. jirovecii. 
Moreover, immunocompetent HCWs may serve as reser-
voirs. P. jirovecii may circulate among patients and staff 
in the hospital, causing colonization in immunocompetent 
staff and pneumonia in immunocompromised patients. 
Studies in laboratory animals and outbreaks of PCP within 
clinical settings support this theory and person-to-person 
transmission as the mode of transmission. If this pattern 
does indeed occur, it would have clinically relevant impli-
cations for hospital infection control policies.
Our study is limited by an imprecise measure of P. 
jirovecii exposure. Most staff can recall direct contact with 
PCP patients but cannot recall transient exposure or indirect 
contact. In addition, asymptomatic persons colonized with P. 
jirovecii may be another source of exposure not recognized 
by HCWs. Our cross-sectional study design and method of 
data collection (participant recall) limit our ability to accu-
rately capture information about P. jirovecii exposure and 
intensity of exposure over time. Comparing hospital staff 
with patient contact to those without patient contact allowed 
us to evaluate whether clinical occupation was independent-
ly associated with P. jirovecii antibody levels. Although the 
nonclinical group had a higher proportion of immunocom-
promising conditions than did the clinical group, this dif-
ference most likely did not influence the results. Whether 
an immunocompromising condition would be associated 
with lower antibody levels caused by impaired antibody 
production or higher antibody levels caused by permissive 
colonization is unclear. Our results suggest that the presence 
of an immunocompromising condition may be associated 
with higher levels. Regardless, including this predictor in 
the multivariate analysis only strengthened the association 
of clinical occupation and MsgC1 levels. Norris and col-
leagues showed that a rise in antibody levels is associated 
with colonization in nonhuman primates (40), and although 
antibody levels may not correlate directly with colonization, 
a similar pattern might occur in humans.
Early serologic studies of P. jirovecii led investigators 
to conclude that PCP results from reactivation of latent in-
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Table 3. Factors associated with MsgC1 levels in a multivariate 
linear regression analysis* 
Factor Estimate (95% CI) p value 
Age >60 y ?1.34 (?2.51 to ?0.16) 0.03 
Male sex 0.44 (?0.03 to 0.91) 0.07 
Asian race 0.42 (?0.12 to 0.95) 0.13 
Clinical occupation 0.89 (0.29 to 1.48) 0.003 
F value 5.15 <0.001 
R2 0.15  
*Msg, major surface glycoprotein; CI, confidence interval. A multivariate 
linear regression was generated by using the natural log of Msg levels as 
the dependent variable and including those predictor variables with p<0.10 
in bivariate analysis. Participants in this cross-sectional study were 
healthcare staff recruited during January 2007–February 2008 from San 
Francisco General Hospital. 
Figure 2. Major surface glycoprotein C1 (MsgC1) levels by 
occupation. Geometric mean MsgC1 levels are shown for nonclinical 
and clinical staff, by job title.
RESEARCH
fection; however, our data add to more recent studies sug-
gesting that PCP may be acquired from recent exposure. 
Higher antibody levels in clinical staff than in nonclinical 
staff may be evidence of patient-to-provider transmission 
of P. jirovecii. Furthermore, evidence from animal mod-
els suggests that parallel provider-to-patient transmission 
could occur with immunocompromised patients. Future 
studies should use serologic assays, such as the MsgC1 
assay, as epidemiologic tools to assess P. jirovecii expo-
sure in HCWs longitudinally, in addition to examining di-
rect measures of colonization such as P. jirovecii DNA in 
respiratory specimens. If further data support the pattern 
observed here, clinicians may consider respiratory precau-
tions and respiratory isolation when caring for patients with 
PCP. Preventing P. jirovecii transmission may further de-
crease the incidence of this grave disease.
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etymologia
Kobuvirus
The Japanese term kobu (kō′ bü), meaning hump or knob, was chosen to designate this genus in the family 
Picornaviridae because of the distinctive icosahedral structure of the viruses in this group. The genus contains the 
species Aichi virus and Bovine kobuvirus, and a candidate porcine kobuvirus has been identified. Aichi virus, the 
type species, was first recognized in 1989 as the cause of oyster-associated nonbacterial gastroenteritis in persons 
in the Aichi Prefecture in Japan.
Source:  Mahy B. The dictionary of virology, 4th edition. London: Elsevier; 2009; Pringle CR. Virus taxonomy at the XIth International 
Congress of Virology, Sydney, Australia, 1999. Arch Virol 1999; 144:2066–70.
